Here are the S-3 shelf registrations from ProKidney Corp. (PROK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow PROK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PROK filings page.
ProKidney Corp. has filed a shelf registration for offerings of up to $650,000,000, with sales permitted only after the registration statement becomes effective. After effectiveness, ProKidney may sell up to $200,000,000 of Class A common stock through Jefferies from time to time in an at-the-market offering under a sales agreement; this capacity is included within—not added to—the $650,000,000 shelf. The shelf may be used for Class A common stock, preferred stock, debt securities, warrants, rights or units.
ProKidney intends to use net proceeds, if any, for clinical-trial costs and research and development, continued investment in its drug development platform, pre-commercial and commercial activities including a commercial manufacturing facility, and general corporate purposes, unless an applicable prospectus supplement indicates otherwise. The company describes itself as a late clinical-stage biotechnology company developing rilparencel, which is being evaluated in Phase 3 REGEN-006 (PROACT 1). ProKidney says it has no product candidates approved for sale and has generated no revenue from product sales.